Pseudomonas aeruginosa bacteraemia in patients with hematologic malignancies: risk factors, treatment and outcome

Polydoros Tofas, Michael Samarkos, Evangelia-Theophano Piperaki, Christos Kosmidis, Ioanna-Dionysia Triantafyllopoulou, Maria Kotsopoulou, Aggeliki Pantazatou, Stavroula Perlorentzou, Anastasia Poulli, Maria Vagia, George L Daikos

Research output: Contribution to journalArticlepeer-review


Our aims were to identify factors associated with Pseudomonas aeruginosa (PA) bloodstream infection (BSI) in patients with hematological malignancies and evaluate the outcome of the affected patients. Consecutive patients with hematological malignancies who developed PA BSI were identified. Subsequently, two case-control studies were performed to evaluate the risk factors (i) for PA BSI and (ii) for carbapenem resistant (CR) PA BSI. Patients' outcome was evaluated at 28 days after the onset of bacteraemia. A total of 64 patients with PA BSI (45 caused by CS and 19 by CR organisms) and 128 without PA BSI were enrolled. Patients with rapidly fatal disease, steroid use, neutropenia or prior surgery were more likely to develop PA BSI, whereas patients with previous hospitalization and prior use of fluoroquinolones were more likely to develop CR PA BSI. The 28-day mortality rate was 35.9%. Severity of sepsis was the only independent predictor of adverse outcome.

Original languageEnglish
Pages (from-to)335-341
Number of pages7
JournalDiagnostic Microbiology and Infectious Disease
Issue number4
Early online date11 May 2017
Publication statusPublished - Aug 2017


  • Anti-Bacterial Agents/therapeutic use
  • Bacteremia/drug therapy
  • Carbapenems/therapeutic use
  • Case-Control Studies
  • Drug Resistance, Bacterial/drug effects
  • Female
  • Fluoroquinolones/therapeutic use
  • Hematologic Neoplasms/microbiology
  • Hospitalization
  • Humans
  • Male
  • Middle Aged
  • Pseudomonas Infections/drug therapy
  • Pseudomonas aeruginosa/drug effects
  • Risk Factors
  • Treatment Outcome


Dive into the research topics of 'Pseudomonas aeruginosa bacteraemia in patients with hematologic malignancies: risk factors, treatment and outcome'. Together they form a unique fingerprint.

Cite this